SILO PHARMA, INC. Deferred Offering Costs
SILO PHARMA, INC. (SILO) had Deferred Offering Costs of $260.95 thousand as of 2025-12-31, per its POS AM filed 2026-04-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Deferred Costs, Current
us-gaap:DeferredOfferingCosts · last filed 2026-04-14
- 2025-12-31: Deferred Offering Costs $260.95K.
- 2025-09-30: Deferred Offering Costs $260.95K.
- 2025-06-30: Deferred Offering Costs $260.95K.
- 2024-12-31: Deferred Offering Costs $260.95K.
| Period end | Deferred Offering Costs |
|---|---|
| 2025-12-31 | $260.95K POS AM · filed 2026-04-14 |
| 2025-09-30 | $260.95K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $260.95K 10-Q · filed 2025-08-13 |
| 2024-12-31 | $260.95K 10-K · filed 2025-03-28 |
| 2024-09-30 | $260.95K 10-Q · filed 2024-11-12 |
| 2024-07-31 | $269.45K POS AM · filed 2026-04-14 |
| 2024-07-22 | $269.45K 10-Q · filed 2025-05-09 |
| 2024-07-18 | $269.45K 10-K · filed 2025-03-28 |
| 2024-06-06 | $260.95K 10-Q · filed 2025-05-09 |
| 2024-04-23 | $260.95K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |